Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Eric M. Dube has filed a notice of proposed sale of TVTX common stock under Rule 144. The filing covers 51,865 common shares to be sold through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of 1,560,982.50. The issuer has 89,472,327 shares of common stock outstanding. The shares to be sold were acquired on 01/27/2026 through the cash exercise of an option originally granted on 01/31/2020.
The notice also lists prior sales of the issuer’s common stock by Dube during the past three months. These include 92,872 shares sold on 10/28/2025 for 2,821,217.14, 27,128 shares sold on 10/29/2025 for 817,045.37, and 8,135 shares sold on 01/23/2026 for 244,153.28. By signing, the seller represents that he is not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
Travere Therapeutics insider plans another stock sale. A person identified in the filing plans to sell 8,135 shares of Travere Therapeutics common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of 244,153.28, when 89,472,327 shares were outstanding as of the notice. The shares were acquired on 01/23/2026 via an option granted on 01/31/2020 and paid for in cash.
Over the prior three months, Eric M. Dube at a San Diego address sold 92,872 Travere common shares on 10/28/2025 for 2,821,217.14 and 27,128 shares on 10/29/2025 for 817,045.37. The signer represents they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Travere Therapeutics Chief Legal Officer Elizabeth E. Reed reported an option exercise and share sale in Travere Therapeutics, Inc. common stock. On January 20, 2026, she exercised 10,000 employee stock options at an exercise price of $19.08 per share and received 10,000 shares of common stock.
That same day, she sold 10,000 shares of Travere common stock at a weighted average price of $27.3420 per share under a Rule 10b5-1(c) trading plan adopted on June 16, 2025, tied to a stock option grant from January 4, 2017 that expires on January 4, 2027. After these transactions, she directly beneficially owned 90,270 shares of common stock, which include 392 shares acquired through the 2017 Employee Stock Purchase Plan, and held 30,000 employee stock options that are fully vested and exercisable.
A holder of TVTX common stock has filed a notice to sell 10,000 shares under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an indicated aggregate market value of $273,420.00. The filing shows 89,472,327 shares of this class outstanding.
The 10,000 shares were acquired from the issuer on 01/20/2026 through a stock option exercise paid in cash on the same date, and are the securities covered by this planned sale.
Travere Therapeutics reported that the U.S. FDA has extended the review timeline for its supplemental New Drug Application for FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS). The new PDUFA target action date is April 13, 2026, following the company’s recent submission of additional information requested by the FDA to further characterize FILSPARI’s clinical benefit.
The FDA classified the submission as a Major Amendment to the application and extended the review period accordingly, and has not requested any new safety or manufacturing data. If ultimately approved, FILSPARI would be the first medication indicated for FSGS, a rare kidney disease with no FDA-approved pharmacologic therapies, and would add to FILSPARI’s existing full approvals in the U.S. and EU for slowing kidney function decline in adults with IgA nephropathy.
Travere Therapeutics, Inc. filed a current report stating that on January 12, 2026 it issued a press release with certain preliminary financial results for the fourth quarter and full year ended December 31, 2025. The company is furnishing this information under a section that keeps the press release and related details from being treated as formally filed or automatically incorporated into other regulatory documents. The press release is included as Exhibit 99.1, and the report also includes a cover page interactive data file as Exhibit 104.
Travere Therapeutics Inc. received a Schedule 13G filing showing that FMR LLC and Abigail P. Johnson beneficially own 10,567,302.78 shares of its common stock, representing 11.7% of the class as of 12/31/2025. FMR LLC reports sole voting power over 10,224,163.76 shares and sole dispositive power over 10,567,302.78 shares, while Abigail P. Johnson reports sole dispositive power over the same 10,567,302.78 shares.
The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Travere Therapeutics. It also notes that one or more other persons may have the right to receive dividends or proceeds from these shares, but no single such person holds more than five percent of the outstanding common stock.
Travere Therapeutics’ Chief Medical Officer sells shares tied to equity awards and a trading plan. Reporting person Jula Inrig, Chief Medical Officer of Travere Therapeutics, Inc., reported two sales of common stock. On January 5, 2026, 2,031 shares were sold at $40.18 per share, and on January 6, 2026, 445 shares were sold at $37.75 per share. After these transactions, the reporting person held 86,311 shares of common stock directly.
According to the footnotes, the January 5 sale reflects shares sold to cover tax withholding owed when restricted stock units vested, under the company’s equity incentive plan and a mandated “sell to cover” arrangement, and is described as not a discretionary trade. The January 6 sale was made under a written plan adopted on May 28, 2025 that is intended to comply with Rule 10b5-1(c), and it also includes shares sold to cover tax obligations from vesting restricted stock units.
Travere Therapeutics, Inc. reported an insider stock sale by its SVP and Chief Accounting Officer. On 12/15/2025, the executive sold 2,910 shares of Travere common stock at $36 per share, according to a Form 4 insider trading report.
After this transaction, the officer beneficially owns 45,635 shares directly. The filing notes that the sale was made under a written trading plan adopted on June 10, 2025 that meets the requirements of Rule 10b5-1(c) under the Securities Exchange Act of 1934.
Travere Therapeutics, Inc. reported an insider stock transaction by its Chief Financial Officer on 12/01/2025. The CFO exercised an employee stock option to acquire 20,000 shares of common stock at an exercise price of $16.23 per share, then sold 20,000 shares of common stock the same day. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on May 28, 2025 and related to an option grant originally made on May 19, 2016.
The weighted average sale price was $35.0101 per share, with individual sale prices ranging from $34.64 to $35.41. Following these transactions, the CFO directly beneficially owned 92,083 shares of Travere Therapeutics common stock.